medRxiv PreprintsInternational15 November 2026
FlahyRecovery is an AI & gene expression based immune profiling biomarker for decision support in precision oncology
This is an official announcement record
Firsthand records what medRxiv Preprints announced and links to the original. The wording below is theirs, not ours.
Background Accurate characterization of the tumor microenvironment (TME) is crucial for inferring tumor biology, subsequent tumor behavior, and predicting therapeutic response. Current characterization methods are inadequate in capturing the complexity of immune signaling networks, hindering robust clinical decision making. To address this, we have developed FlahyRecovery - an artificial intelligence (AI) and gene expression based immune profiling biomarker, implemented via a supervised classification machine learning model, that integrates response prediction and prognostic insights to person
Read the official announcement
Opens www.medrxiv.org
More from medRxiv Preprints
- Unmet needs of Polish patients with cystic fibrosis seen through the lens of crowdfunding20 November 2026
- Motherly Plus: Study Protocol of a Randomized Controlled Trial Evaluating a Smartphone-Assisted Single-Session Psychotherapy Intervention for Postpartum Depression20 November 2026
- Targeting memory consolidation in major depression via pharmacological slow-wave sleep promotion20 November 2026
- Epidemiology of Cardiac Structure and Function Among African Caribbeans in Tobago: A Population-based Cohort Study20 November 2026
- Depressive Symptom Trajectories and Incident Cognitive Impairment by Outcome Ascertainment20 November 2026
This content is for informational purposes only and is not medical advice. It is not intended to diagnose, treat, cure, or prevent any disease. Consult a healthcare professional before starting any supplement, treatment, or program: especially if you are pregnant, nursing, taking medication, or managing a health condition.